Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis

Brain

Volumn 121, Issue 12, 1998, Pages 2327-2334

  Leppert, David ^a   Ford, Janice ^b   Stabler, Gary ^b   Grygar, Caroline ^a   Lienert, Carmen ^a   Huber, Susanne ^a   Miller, Karen M ^b   Hauser, Stephen L ^c   Kappos, Ludwig ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CSF matrix metalloproteinases; Multiple sclerosis; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; PROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; BASEMENT MEMBRANE; BRAIN TISSUE; CELL INVASION; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GEL ELECTROPHORESIS; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PARENCHYMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RELAPSE; T LYMPHOCYTE; TISSUE INJURY;

EID: 0031798063     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/121.12.2327     Document Type: Article

References (45)

1. Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-b la from mammalian cells. Cytokines Cell Mol Ther 1997; 3: 27-32.
2. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour necrosis factor-ex from cells. Nature 1997; 385: 729-33.
3. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995; 201: 223-6.
4. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor. J Neuroimmunol 1997; 74: 85-94.
5. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 1997; 94: 590-8.
6. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, et al. The expression of tissue-type plasminogen-activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55: 1194-204.
7. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34.
8. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994; 94: 2177-82.
9. Goodkin DE. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. [Review]. West J Med 1994; 161: 292-8.
10. Hartung HP. Pathogenesis of multiple sclerosis. In: Abramsky O, Ovadia H, editors. Frontiers in multiple sclerosis. London: Martin Dunitz; 1997. p. 45-60.
11. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995; 44: 345-9.
12. Hughes RA, Sharrack B. More immunotherapy for multiple sclerosis [editorial: comment]. [Review]. J Neurol Neurosurg Psychiatry 1996; 61: 239-41. Comment on: J Neurol Neurosurg Psychiatry 1996; 61: 251-8.
13. Hughes RA, Sharrack B. More immunotherapy for multiple sclerosis [editorial: comment]. [Review]. J Neurol Neurosurg Psychiatry 1996; 61: 239-41. Comment on: J Neurol Neurosurg Psychiatry 1996; 61: 251-8.
14. Hughes PM, Wells GMA, Clements JM, Gearing AJH, Redford EJ, Davies M, et al. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998; 121: 481-94.
15. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with Interferon beta-1b: experience during the first three years [see comments]. Neurology 1996; 47: 889-94. Comment in: Neurology 1996; 47: 865-6, Comment in: Neurology 1997; 49: 641-2.
16. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with Interferon beta-1b: experience during the first three years [see comments]. Neurology 1996; 47: 889-94. Comment in: Neurology 1996; 47: 865-6, Comment in: Neurology 1997; 49: 641-2.
17. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with Interferon beta-1b: experience during the first three years [see comments]. Neurology 1996; 47: 889-94. Comment in: Neurology 1996; 47: 865-6, Comment in: Neurology 1997; 49: 641-2.
18. Johnatty RN, Taub DD. Reeder SP, Turcovski-Corrales SM. Cottam DW, Stephenson TJ. et al. Cytokine and chemokine regulation of proMMP-9 and T1MP-1 production by human peripheral blood lymphocytes, J Immunol 1997; 158: 2327-33.
19. Kermode AG, Thompson AJ, Tofts P, MacManus DG. Kendall BE, Kingsley DP, et al, Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113: 1477-89.
20. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GMA. Schweitzer T, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998; 121:159-66.
21. Kolb SA, Lahrtz F, Paul R, Leppert D, Nadal D, Pfister HW, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol 1998; 84: 143-50.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
23. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuroparhol Exp Neurol 1994; 53: 625-36.
24. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995; 154: 4379-89.
25. Leppert D, Waubant E, Bürk M, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52.
26. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 300-9.
27. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines [see comments]. J Neurol Neurosurg Psychiatry 1991; 54: 683-8. Comment in: J Neurol Neurosurg Psychiatry 1992; 55: 978.
28. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines [see comments]. J Neurol Neurosurg Psychiatry 1991; 54: 683-8. Comment in: J Neurol Neurosurg Psychiatry 1992; 55: 978.
29. Montgomery AM, Sabzevari H, Reisfeld RA. Production and regulation of gelatinase B by human T-cells. Biochim Biophys Acta 1993; 1176: 256-68.
30. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α [published erratum appears in Nature 1997; 386: 738]. Nature 1997; 385: 733-6.
31. Paemen L, Olsson T, Söderström M, Van Damme J, Opdenukker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol 1994; 1: 55-63
32. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
33. Proost p, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993; 192: 1175-81.
34. Redford EJ, Smith KJ, Gregson NA, Davies M, Hughes P, Gearing AJ, et al. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-α processing attenuates experimental autoimmune neuritis. Brain 1997; 120: 1895-905.
35. Rosenberg GA, Kornfeld K Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576: 203-7.
36. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. Tumor necrosis factor-α induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 1995; 703: 151-5.
37. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996; 46: 1626-32.
38. Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63.
39. Tuohy VK, Fritz RB, Ben-Nun A. Self-determinants in autoimmune demyelinating disease: changes in T-cell response specificity. [Review]. Curr Opin Immunol 1994; 6: 887-91.
40. Welgus H, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest 1990; 86: 1496-502.
41. Wells GM, Catlin G, Cossins JA, Mangan M, Ward GA, Miller KM, et al. Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multi-competitor cDNA standard. Glia 1996; 18: 332-40.
42. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25: 43-9.
43. Xia M, Leppert D, Hauser SL, Sreedharan SP, Nelson PJ, Krensky AM, et al. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J Immunol 1996; 156: 160-7.
44. Xie B, Dong Z, Fidler U. Regulatory mechanisms for the expression of type IV collagenases/gelatinases in murine macrophages. J Immunol 1994; 152: 3637-44.
45. Yong VW, Krekoski CA, Forsyth PA. Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998; 21: 75-80.